Screener
Hemab Therapeutics Holdings, Inc. COAG Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Principal payments on finance lease | (46) | (59) |
| Net cash provided by (used in) financing activities | 317,119 | (59) |
| Effect of foreign exchange rate changes on cash and cash equivalents | (222) | - |
| Net increase (decrease) in cash and cash equivalents | 149,392 | (12,917) |
| Cash and cash equivalents at beginning of period | 87,974 | 74,407 |
| Cash and cash equivalents at end of period | $237,366 | $61,490 |
| Supplemental disclosure of cash flow activities | ||
| Cash paid for interest | - | $7 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s net change in cash?
- Hemab Therapeutics Holdings, Inc. (COAG) reported net change in cash of $187.51M in Q2 2026.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude